·药物研究动态·

潘长玉

作者单位：100853北京，解放军总医院内分泌科

【提要】 利拉鲁肽作为长效人胰升血糖素样肽-1(GLP-1)类似物，具有葡萄糖浓度依赖性的降糖效应和改善β细胞功能、减重、降压、降脂等多种降糖外效应。大型临床三期LEAD试验研究证实，利拉鲁肽无论是单独使用还是联合用药，除具良好的降糖效应外，还可减少低血糖事件的发生，发挥全面的心血管保护作用，其疗效无年龄依赖性，总体耐受性好，治疗过程中抗体滴度低，且目前尚无确切证据表明利拉鲁肽与急性胰腺炎和甲状腺C细胞癌相关。利拉鲁肽良好的疗效和安全性，为2型糖尿病患者提供了新的治疗方案。

【关键词】 人胰升糖素样肽-1,利拉鲁肽,LEAD研究,低血糖,降糖外效应

doi:10.3969/j.issn.1006-6187.2011.07.022

The review on safety of the human long-acting GLP-1 analogue, Liraglutide

PAN Chang-yu. Department of Endocrinology and Metabolism, Chinese PLA General Hospital, Beijing 100853， China

【Summary】 Liraglutide, as a human long-acting GLP-1 analogue, has a glucose-lowering efficacy in a glucose-dependent manner and other extra effects, such as improving β cell function, losing weight, lowering blood pressure, and lowering blood lipid. The large third phase clinical study in many countries, LEAD research, proves that liraglutide has many effects, including reducing hyperglycemia along with a low occurrence of hypoglycemia without age-dependent influence, providing protections of cardiovascular system, possessing a well tolerability in general group, and producing low titer of antibody regardless of using alone or combining with other oral hypoglycemic agents. Currently, there is no exact evidence to show that Liraglutide is related with acute pancreatitis or thyroid C-cell carcinoma. Therefore, Liraglutide provides a new way to treat patients with type 2 diabetes due to the good efficacy and safety.

【Key words】 Glucagon like peptide-1; Liraglutide; LEAD Study; Hypoglycemia; Extra Effects